66 reports

  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Oncology
  • Targeted Therapy
  • United States
  • Product Initiative
  • Apexigen, Inc.

MP## is currently in phase ##.

  • Immunotherapy
  • Targeted Therapy
  • United States
  • Product Initiative
  • Apexigen, Inc.

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Oncology
  • Targeted Therapy
  • United States
  • Product Initiative
  • Apexigen, Inc.

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Arthritis
  • Targeted Therapy
  • Therapy
  • United States
  • Bristol-Myers Squibb Company
  • 5. All the trials included are unique trials.
  • Clinical Trial Profile Snapshots

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Incyte Corp ## ## ## ## ## ## ## ## Bellicum Pharmaceuticals Inc ## ##

  • Cardiovascular Drug
  • Pharmaceutical
  • Targeted Therapy
  • Transplantation
  • United States
  • EVEROLIMUS - DRUG PROFILE

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Bristol-Myers Squibb Company

Eligible patients had confirmed ATTR-CM and NYHA Class II or III symptoms, and at least one prior heart failure hospitalization or active treatment for chronic heart failure.

  • Cardiovascular Drug
  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Alnylam Pharmaceuticals, Inc.

The study included ## subjects of age ## or greater undergoing cardiac surgery and at risk for AKI, randomized in a ##:## ratio to QPI-## or placebo.

  • Cardiovascular Drug
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • EVEROLIMUS - DRUG PROFILE

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Liver transplant replaces an injured or diseased liver with a healthy one.

  • Digestive System Disorder
  • General Medicine And Specialty Medicine
  • Targeted Therapy
  • United States
  • Product Initiative

The study included ## subjects of age ## or greater undergoing cardiac surgery and at risk for AKI, randomized in a ##:## ratio to QPI-## or placebo.

  • Cardiovascular Drug
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

The reduced weight gain was seen both one and two years after transplant.

  • Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Phase I - Trial Details

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

The purpose of one Phase I study is to evaluate cardiac safety of brentuximab vedotin (SGN-##) in patients with CD##-positive cancers.

  • Cardiovascular Drug
  • Targeted Therapy
  • Transplantation
  • United States
  • Pluristem Therapeutics Inc.

The second was a patient in the ## mg dose group who presented with fever and diarrhea, subsequent heart failure and presumed pulmonary embolism (PE) during hospitalization.

  • Cardiovascular Drug
  • Targeted Therapy
  • Therapy
  • United States
  • Incyte Corporation

One patient developed symptomatic congestive heart failure.

  • Lung Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

One patient developed symptomatic congestive heart failure.

  • Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • Phase I - Trial Details

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • EVEROLIMUS - DRUG PROFILE

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine micro emulsion in cardiac transplant recipients.

  • Cardiovascular Drug
  • Lymphoma
  • Targeted Therapy
  • United States
  • Merck & Co., Inc.

NON CARDIAC DLTS WERE FATIGUE AND ABNORMAL LIVER FUNCTION TESTS.

  • Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Merck & Co., Inc.

The reduced weight gain was seen both one and two years after transplant.

  • Cardiovascular Drug
  • Lung Cancer
  • Targeted Therapy
  • United States
  • Product Initiative

A third patient had a cardiac event (acute cardiac failure) during the first cycle and continued on CHOP alone.

  • Cardiovascular Drug
  • Hepatitis
  • Targeted Therapy
  • United States
  • Merck & Co., Inc.

The reduced weight gain was seen both one and two years after transplant.

  • Cancer
  • Cardiovascular Drug
  • Targeted Therapy
  • United States
  • Product Initiative
  • EVEROLIMUS - DRUG PROFILE

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Cardiovascular Drug
  • Targeted Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Mechanism of Action Astellas Pharma Inc is developing small molecule for heart transplantation.

  • Cardiovascular Drug
  • Cell Therapy
  • Targeted Therapy
  • United States
  • Astellas Pharma Inc.
  • EVEROLIMUS - DRUG PROFILE

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Targeted Therapy
  • United States
  • Company Operations
  • Product Initiative
  • Novartis AG

Patients will be randomized in a ##:##:## fashion to placebo or one of two different doses of AG## on a background of stable heart failure therapy.

  • Cardiovascular Drug
  • Endocrine Disease
  • Targeted Therapy
  • United States
  • Product Initiative
  • Mechanism Of Action

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Cancer
  • Cardiovascular Drug
  • Targeted Therapy
  • United States
  • Merck & Co., Inc.
  • EVEROLIMUS - DRUG PROFILE

The primary outcome measure is to determine that any of the following complications after heart transplantation wound healing complications, pleural effusions (by chest X ray), pericardial effusions (by cardiac ultrasound), acute renal insufficiency by glomerular filtratio

  • Digestive System Disorder
  • Targeted Therapy
  • United States
  • Product Initiative
  • Novartis AG